Study objectives To determine whether tobramycin solution for inhalation (TSI) can be
administered safely and more efficiently with a new-generation aerosol device, the …

Study objectives To describe the pharmacokinetics and bioavailability of inhaled tobramycin
(TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI LC …

BACKGROUND: Tobramycin powder for inhalation (TIP) is a drug-device combination
designed to reduce treatment time and improve ease of use compared with tobramycin …

BACKGROUND: Nebulization times have been identified as an issue in patient compliance
with tobramycin solution for inhalation (TSI) therapy in cystic fibrosis (CF). METHODS: In this …

Background: Dosing of tobramycin solution for inhalation (TSI) in cystic fibrosis (CF) patients
was based on single-dose pharmacokinetic studies. This investigation was prompted by …

BACKGROUND: A light-porous-particle, dry-powder formulation of tobramycin was
developed, using PulmoSphere® technology, to improve airway delivery efficiency …

Tobramycin nebuliser solution (TNS) has been investigated in several clinical trials,
including a large, placebo-controlled study that demonstrated efficacy over a 24-week …

Cystic fibrosis patients suffer increased sputum production and a notable decline in
respiratory function throughout the progression of their disease. Patients are left vulnerable …

This study was performed to determine the clinical pharmacokinetics of tobramycin in six
patients with cystic fibrosis (CF) after inhalation of 600 mg. Tobramycin was administered …

Abstract OBJECTIVE: Two identical 24-week, double-blind, placebo-controlled trials of
tobramycin solution for inhalation (TOBI® PathoGenesis Corporation, Seattle, Washington) …